Acute Myelomonocytic Leukemia
Symptoms, Doctors, Treatments, Advances & More

Acute Myelomonocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Myelomonocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Myelomonocytic Leukemia?
A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially hepatosplenomegaly, and lymphadenopathy may also be associated.
What are the alternative names for Acute Myelomonocytic Leukemia?
  • Acute myelomonocytic leukemia
  • Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML M4
  • AML-M4
  • AMMoL
  • Acute myeloblastic leukemia type 4
  • AML with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)
  • Acute myelomonocytic leukemia
  • CBFB-MYH11
Who are the top Acute Myelomonocytic Leukemia Local Doctors?
Naval Daver
Elite in Acute Myelomonocytic Leukemia
Dr. Naval Daver
Oncology
Elite in Acute Myelomonocytic Leukemia
Dr. Naval Daver
Oncology

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
713-794-4392
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naval Daver is an Oncologist in Houston, Texas. Dr. Daver is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Elite in Acute Myelomonocytic Leukemia
Dr. Robert Fram
Hematology
Elite in Acute Myelomonocytic Leukemia
Dr. Robert Fram
Hematology

Office

128 Sidney St, 
Cambridge, MA 
617-995-4909
Languages Spoken:
English

Robert Fram is a Hematologist in Cambridge, Massachusetts. Dr. Fram is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Myelomonocytic Leukemia
Dr. Douglas Faller
Hematology
Elite in Acute Myelomonocytic Leukemia
Dr. Douglas Faller
Hematology

Office

720 Harrison Ave, 
Boston, MA 
617-638-6428
Languages Spoken:
English
See accepted insurances

Douglas Faller is a Hematologist in Boston, Massachusetts. Dr. Faller is rated as an Elite provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML).

View All Doctors
What are the latest Acute Myelomonocytic Leukemia Clinical Trials?
Single-center, Biological, Uncontrolled, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 (FMS-like Tyrosine Kinase 3) Ligand and IL6 With a View to Making a First Estimate of Their Prognostic Value on the Outcome of Patients Treated With Non-intensive Chemotherapy Such as Azacytidine for Acute Myelogenous Leukemia (AML), High Risk Myelodysplastic Syndrome (HR-MDS) or Chronic Myelomonocytic Leukemia (CMML)
Single-center, Biological, Uncontrolled, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 (FMS-like Tyrosine Kinase 3) Ligand and IL6 With a View to Making a First Estimate of Their Prognostic Value on the Outcome of Patients Treated With Non-intensive Chemotherapy Such as Azacytidine for Acute Myelogenous Leukemia (AML), High Risk Myelodysplastic Syndrome (HR-MDS) or Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Recruiting
Publish Date: April 16, 2026

Summary: There are 2 possible treatments for the treatment of Acute Myelogenous Leukemia (AML), high-risk myelodysplastic syndromes (HR-MDS) or chronic myelomonocytic leukemia (CMML): intensive curative chemotherapy , and for over-aged or co-morbid patients , non-intensive palliative chemotherapy with a hypomethylating agent (Azacytidine) associated or not with venetoclax. Pro-inflammatory cytokines and in...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
Who is this study for: Adult patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: March 30, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Cytarabine, Decitabine, Filgrastim, Fludarabine, Gemtuzumab, Idarubicin
Study Phase: Phase 2

Summary: This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin hydrochloride, work in different ways to st...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center